USSTOCK.TODAY
Market Closed
Log in Sign up

Relmada Therapeutics Beats Q3 EPS Estimates and Maintains NDV-01 Timeline

Earnings Whispers · ·by G4L

RLMD
RLMD Relmada Therapeutics Inc
$4.21 +1.20%
View chart & analysis →
  1. 1Relmada Therapeutics reported a Q3 loss per share of $0.12.
  2. 2Relmada Therapeutics maintained its late 2026 IND timeline for NDV-01.
  3. 3Two BCG-naïve T1 patients progressed to T2a muscle-invasive disease at the 15-month evaluation.

So what's the key point?

Relmada Therapeutics reported a smaller loss than expected. The development plan for its new drug is also proceeding as scheduled.

Source Earnings Whispers · View original ↗

Related 3-line summaries

Rank One Computing Turns Profitable in Q3 with 50% Revenue Increase Earnings Whispers · 1h agoGrabAGun Digital Holdings misses both Q3 revenue and profitability expectations Earnings Whispers · 1h agoPEDEVCO Corp faces declining production and CEO departure despite revenue growth Earnings Whispers · 1h ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news